Drug Patents owned by Teva Branded Pharm

1. List of Austedo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8524733 TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(8 years from now)

US9550780 TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733

(Pediatric)

TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Oct, 2031

(8 years from now)

US9233959 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(10 years from now)

US9296739 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(10 years from now)

US9814708 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(10 years from now)

US9296739

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(11 years from now)

US9233959

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(11 years from now)

US9550780

(Pediatric)

TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(11 years from now)

US9814708

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(11 years from now)

US11357772 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(13 years from now)

US10959996 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(13 years from now)

US11446291 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(13 years from now)

US11357772

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(13 years from now)

US10959996

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(13 years from now)

US11179386 TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Mar, 2038

(15 years from now)

US11179386

(Pediatric)

TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Sep, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 3, 2024
New Chemical Entity Exclusivity (NCE) Apr 3, 2022
M Jun 24, 2024
Pediatric Exclusivity (PED) Oct 3, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: October, 2023

Market Authorisation Date: 03 April, 2017

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET;ORAL

How can I launch a generic of AUSTEDO before it's patent expiration?
More Information on Dosage

2. List of Loseasonique drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615545 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Jun, 2023

(4 months from now)

US7858605 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Jun, 2023

(4 months from now)

US7855190 TEVA BRANDED PHARM Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
Dec, 2028

(5 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 24 October, 2008

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

How can I launch a generic of LOSEASONIQUE before it's patent expiration?
More Information on Dosage

3. List of Proair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7540282 TEVA BRANDED PHARM Reservoir pressure system for medicament inhaler
May, 2023

(2 months from now)

US9463288 TEVA BRANDED PHARM Dry powder inhalation apparatus
May, 2025

(2 years from now)

US10765820 TEVA BRANDED PHARM Dry powder inhalation apparatus
May, 2025

(2 years from now)

US8651103 TEVA BRANDED PHARM Dry powder inhalation apparatus
Mar, 2028

(5 years from now)

US9731087 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(8 years from now)

US10124131 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(8 years from now)

US9216260 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(8 years from now)

US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(8 years from now)

US8978966 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(8 years from now)

US9782551 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(12 years from now)

US9782550 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(12 years from now)

US10918816 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler
Dec, 2035

(12 years from now)

US10569034 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2036

(13 years from now)

US11351317 TEVA BRANDED PHARM Drug delivery device with electronics
Feb, 2038

(15 years from now)

US11357935 TEVA BRANDED PHARM Drug delivery device with electronics
Sep, 2038

(15 years from now)

US11000653 TEVA BRANDED PHARM Inhaler
Dec, 2038

(15 years from now)

US11344685 TEVA BRANDED PHARM Drug delivery device with electronics
Sep, 2039

(16 years from now)

US11439777 TEVA BRANDED PHARM Drug delivery device with electronics
May, 2040

(17 years from now)

US11464923 TEVA BRANDED PHARM Inhaler system
Jun, 2040

(17 years from now)

US11173259 TEVA BRANDED PHARM Drug delivery device with electronics and power management
Jul, 2040

(17 years from now)

US11266796 TEVA BRANDED PHARM Inhalation device with integrated electronics
Feb, 2041

(18 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

4. List of Proair Hfa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7105152 TEVA BRANDED PHARM Suspension aerosol formulations
Sep, 2023

(7 months from now)

US8132712 TEVA BRANDED PHARM Metered-dose inhaler
Sep, 2028

(5 years from now)

US10695512 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US11395889 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US9463289 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(8 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(8 years from now)

US10086156 TEVA BRANDED PHARM Dose counter for inhaler and method for counting doses
May, 2031

(8 years from now)

US9808587 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US10022509 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(8 years from now)

US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(8 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 29 October, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of PROAIR HFA before it's patent expiration?
More Information on Dosage

5. List of Qnasl drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7780038 TEVA BRANDED PHARM Dispensing apparatus with dosage counter
Jan, 2027

(3 years from now)

US10188811 TEVA BRANDED PHARM Nasal spray device
Oct, 2031

(8 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 23 March, 2012

Treatment: NA

Dosage: AEROSOL, METERED;NASAL

More Information on Dosage

6. List of Quartette drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450299 TEVA BRANDED PHARM Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Oct, 2025

(2 years from now)

US8415332 TEVA BRANDED PHARM Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Mar, 2029

(6 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 28 March, 2013

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

How can I launch a generic of QUARTETTE before it's patent expiration?
More Information on Dosage

7. List of Qvar 40 drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808587 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US10086156 TEVA BRANDED PHARM Dose counter for inhaler and method for counting doses
May, 2031

(8 years from now)

US11395889 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US9463289 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(8 years from now)

US10022509 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(8 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(8 years from now)

US10695512 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(8 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 15 September, 2000

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of QVAR 40 before it's patent expiration?
More Information on Dosage

8. List of Seasonique drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615545 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Jun, 2023

(4 months from now)

US7858605 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Jun, 2023

(4 months from now)

US7320969 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Jan, 2024

(11 months from now)

US7855190 TEVA BRANDED PHARM Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
Dec, 2028

(5 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 25 May, 2006

Treatment: Prevention of pregnancy; Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception

Dosage: TABLET;ORAL

How can I launch a generic of SEASONIQUE before it's patent expiration?
More Information on Dosage

9. List of Vantrela Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216176 TEVA BRANDED PHARM Abuse resistant drug formulation
Sep, 2027

(4 years from now)

US9572803 TEVA BRANDED PHARM Abuse resistant drug formulation
Sep, 2027

(4 years from now)

US8445018 TEVA BRANDED PHARM Abuse resistant drug formulation
Jul, 2029

(6 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 17 January, 2017

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

10. List of Zecuity drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6745071 TEVA BRANDED PHARM Iontophoretic drug delivery system
Feb, 2023

(15 days from now)

US8597272 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(4 years from now)

US9427578 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(4 years from now)

US8470853 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds
Apr, 2027

(4 years from now)

US8155737 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(4 years from now)

US7973058 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds
Apr, 2027

(4 years from now)

US9272137 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds
Sep, 2027

(4 years from now)

US8366600 TEVA BRANDED PHARM Polyamine enhanced formulations for triptan compound iontophoresis
Apr, 2029

(6 years from now)

US8983594 TEVA BRANDED PHARM Electronic control of drug delivery system
Nov, 2030

(7 years from now)

US9327114 TEVA BRANDED PHARM User-activated self-contained co-packaged iontophoretic drug delivery system
Oct, 2032

(9 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 17 January, 2013

Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof; Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof, using a flowable hydrogel formulation

Dosage: SYSTEM;IONTOPHORESIS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in